Bronchitis Organism-Specific Therapy 

Updated: Aug 20, 2019
  • Author: Jazeela Fayyaz, DO; Chief Editor: John J Oppenheimer, MD  more...
  • Print

Specific Organisms and Therapeutic Regimens for Bronchitis

Organism-specific therapeutic regimens for bronchitis are provided below. [1, 2, 3, 4, 5, 6, 7]

See Bronchitis for full information.

Acute bronchitis

Most acute bronchitis cases in healthy individuals do not have an identifiable cause; therefore, viral etiology is presumed. Nonetheless, some studies implicate bacterial pathogens in up to 25% of cases. [6]

Viral

  • Influenza virus (especially if associated with fevers, chills, headache, cough, and myalgias)

  • Supportive measures for other viruses (eg, Parainfluenzavirus, respiratory syncytial virus, Coronavirus, Adenovirus, Rhinovirus)

Bordetella pertussis (incubation period of 1-3 weeks, fever is uncommon, suspect if cough persists for >2 weeks) [2] :

  • First-line treatment is macrolides:

    • Azithromycin 500 mg PO on day 1, then 250 mg PO q24h on days 2-5 or

    • Erythromycin 500 mg PO QID for 14 days or

    • Clarithromycin 500 mg PO BID for 7 days

  • Second-line treatment:

Mycoplasma pneumoniae (incubation period 2-3 weeks, gradual onset 2-3 days, occurs in clusters such as military or students) [2] :

  • Azithromycin 500 mg PO on day 1 then 250 mg on days 2-5 or

  • Doxycycline 100 mg PO BID for 5 days or

  • Consider quinolones if local resistance to macrolides [8]

Chlamydophila pneumoniae (incubation period of 3 weeks, gradual onset of hoarseness before cough, occurs in clusters such as military, students, or nursing homes) [2] :

  • Azithromycin 500 mg PO on day 1 then 250 mg on days 2-5 or

  • Doxycycline 100 mg PO BID for 5 days or

  • Supportive measures only

Other organisms identified to cause acute bronchitis include: Streptococcus pneumoniae, Haemophilusinfluenzae, and Moraxella catarrhalis. Treatment is below.

Acute bacterial exacerbation of chronic bronchitis (ABECB)

Always assess for regional resistance prior to choosing antimicrobial treatment.

Haemophilus influenzae and Haemophilus parainfluenzae [7] :

Streptococcus pneumoniae [7] :

Moraxella catarrhalis [7] :

Mycoplasma pneumoniae and Chlamydophila pneumoniae [2] :

  • Macrolides and tetracyclines are drugs of choice:

    • Azithromycin 500 mg PO on day 1 then 250 mg on days 2-5 alternatively 500 mg PO daily for 3 days or

    • Erythromycin 400 mg PO QID for 10 days or

    • Clarithromycin 250-500 mg PO BID for 7-14 days or

    • Doxycycline 100 mg PO BID for 5 days or

  • Less active are fluoroquinolones:

Staphylococcus aureus [7] :

Klebsiella pneumoniae [7] :

Pseudomonas aeruginosa [7] :

Adjunctive therapy

Patients should receive the influenza vaccine yearly between October and December.

Patients aged 65 years or older or with chronic disease should receive pneumococcal vaccines; prevnar 13 and pneumovax 23, when possible prevnar 13 should be given first (separated by at least 1 year). [9]

Next:

Questions & Answers

Overview

What causes acute bronchitis?

What are the organism-specific therapeutic regimens for viral bronchitis?

What are the organism-specific therapeutic regimens for Bordetella pertussis bronchitis?

What are the organism-specific therapeutic regimens for Mycoplasma pneumoniae bronchitis?

What are the organism-specific therapeutic regimens for Chlamydophila pneumoniae bronchitis?

What should be assessed prior to administering antimicrobial treatment for acute bacterial exacerbation of chronic bronchitis (ABECB)?

What are the organism-specific therapeutic regimens for Haemophilus influenzae and Haemophilus parainfluenzae acute bacterial exacerbation of chronic bronchitis (ABECB)?

What are the organism-specific therapeutic regimens for Moraxella catarrhalis acute bacterial exacerbation of chronic bronchitis (ABECB)?

What are the organism-specific therapeutic regimens for Streptococcus pneumoniae acute bacterial exacerbation of chronic bronchitis (ABECB)?

What are the organism-specific therapeutic regimens for Mycoplasma pneumoniae and Chlamydophila pneumoniae acute bacterial exacerbation of chronic bronchitis (ABECB)?

What are the organism-specific therapeutic regimens for Staphylococcus aureus acute bacterial exacerbation of chronic bronchitis (ABECB)?

What are the organism-specific therapeutic regimens for Klebsiella pneumoniae acute bacterial exacerbation of chronic bronchitis (ABECB)?

What are the organism-specific therapeutic regimens for Pseudomonas aeruginosa acute bacterial exacerbation of chronic bronchitis (ABECB)?

What are the adjunctive therapies used in the treatment of bronchitis?

Previous